Drug Discovery & DDS– category –
-
DelveInsight Reports Over 80 Molecular Glue Drug Candidates in Clinical Pipeline, Highlighting Market Boom
GlobeNewswire USA Overview DelveInsight's comprehensive report reveals over 80 molecular glue drug candidates in clinical development, signifying rapid expansion in this novel therapeutic modality. Key advancements include Nested Therape... -
Drug Discovery & DDS Weekly Report July 19, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report July 19, 2026 (PDF) — Download Weekly Report July 19, 2026 (PDF) — DownloadDownload 🎙 Podcast July 19, 2026 (... -
Antibody-Drug Conjugates (ADCs) Evolve to Standard of Care in Solid Tumor Treatment: 12 Approved, 300 in Development, Focusing on Patient Wellness and Dual-Payload Strategies
Cancer News - Binaytara USA Overview Antibody-drug conjugates (ADCs) have dramatically evolved from 'magic bullets' to a standard of care in cancer treatment, with 12 ADCs approved globally and over 300 in clinical development. This evol... -
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
AI Transforms Drug Discovery: Generative AI Accelerates Molecule Design to Clinical Prediction, Reducing R&D Costs and Risks
World Pharma Today Unknown Overview AI, particularly generative AI, is fundamentally transforming drug discovery in 2026 by accelerating target identification, molecule design, and outcome prediction. AI-driven platforms computationally ... -
SGN-CEACAM5C (PF-08046050) Antibody-Drug Conjugate Evaluated in Phase 1 Clinical Trial for Advanced Solid Tumors Including Colorectal Cancer
Fight Colorectal Cancer USA Overview The July 2026 clinical trials roundup highlighted the evaluation of SGN-CEACAM5C (PF-08046050), an antibody-drug conjugate (ADC), in a Phase 1 study for adult patients with advanced solid tumors, incl... -
Phase 2 OPTIMAL-e Study Begins Dosing in Metastatic Hormone-Sensitive Prostate Cancer to Assess Adaptive Lutetium-177 PSMA RLT
Urology Times USA Overview The Phase 2 OPTIMAL-e study has commenced dosing patients with metastatic hormone-sensitive prostate cancer (mHSPC) to evaluate an adaptive treatment approach using the investigational PSMA-targeted radioligand... -
GZL626, a Novel Molecular Glue Degrader for Androgen Receptor (AR/AR-V7), Overcomes Resistance in Advanced Prostate Cancer
bioRxiv Unknown Overview A preprint on bioRxiv describes the identification of GZL626, a novel small-molecule molecular glue degrader that induces proteasome-dependent degradation of both full-length androgen receptor (AR) and its splice... -
ChemRxiv Unveils AI Workflow for Structure-Aware Small-Molecule Drug Design: Integrating Agentic, Explainable, and Generative AI for Design to Prioritization
ChemRxiv Unknown Overview A preprint on ChemRxiv describes an innovative AI workflow for structure-aware small-molecule drug design, integrating agentic and explainable machine learning with generative molecular design. This system autom... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and...
